利伐沙班与心力衰竭、冠心病及窦性心律患者血栓栓塞事件的关联:COMMANDER HF 试验的事后分析
COMMANDER HF 试验的事后分析纳入 5022 例近期心力衰竭加重、冠心病及窦性心律患者,随机接受利伐沙班 2.5 mg 每日两次或安慰剂。
要点
- 在心力衰竭、冠心病及窦性心律患者中,血栓栓塞事件较常见。
- 低剂量利伐沙班可能降低血栓栓塞事件风险,但需前瞻性随机试验证实。
- 利伐沙班对心力衰竭加重患者的主要致病和致死原因无影响。
核心结论
- 在心力衰竭、冠心病及窦性心律患者中,血栓栓塞事件较常见,利伐沙班可能降低其风险,但这些事件并非近期心力衰竭加重患者的主要致病和致死原因,利伐沙班对此无影响,结果需前瞻性随机临床试验证实。
研究设计与样本
- COMMANDER HF 多中心、随机、双盲、安慰剂对照试验的事后分析,共随机 5022 例因心力衰竭加重住院或门诊治疗后出院的患者,1:1 随机接受利伐沙班 2.5 mg 每日两次或安慰剂。
临床怎么用
- 对于心力衰竭、冠心病及窦性心律患者,利伐沙班可能减少血栓栓塞事件,但该适应症尚未确立,需等待前瞻性随机试验验证。
局限性
- 本分析为事后分析,结果需前瞻性随机临床试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is uncertain. The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm. Although the primary end point of all-cause mortality, myocardial infarction, or stroke did not differ between rivaroxaban and placebo, there were numerical advantages favoring rivaroxaban for myocardial infarction and stroke. OBJECTIVE: To examine whether low-dose rivaroxaban was associated with reduced thromboembolic events in patients enrolled in the COMMANDER HF trial. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of the COMMANDER HF multicenter, randomized, double-blind, placebo-controlled trial in patients with CAD and worsening HF. The trial randomized 5022 patients postdischarge from a hospital or outpatient clinic after treatment for worsening HF between September 2013 and October 2017. Patients were required to be receiving standard care for HF and CAD and were excluded for a medical condition requiring anticoagulation or a bleeding history. Patients were randomized in a 1:1 ratio. Analysis was conducted from June 2018 and January 2019. INTERVENTION: Patients were randomly assigned to receive 2.5 mg of rivaroxaban given orally twice daily or placebo in addition to their standard therapy. MAIN OUTCOMES AND MEASURES: For this post hoc analysis, a thromboembolic composite was defined as either (1) myocardial infarction, ischemic stroke, sudden/unwitnessed death, symptomatic pulmonary embolism, or symptomatic deep venous thrombosis or (2) all of the previous components except sudden/unwitnessed deaths because not all of these are caused by thromboembolic events. RESULTS: Of 5022 patients, 3872 (77.1%) were men, and the overall mean (SD) age was 66.4 (10.2) years. Over a median (interquartile range) follow-up of 19.6 (11.7-30.8) months, fewer patients assigned to rivaroxaban compared with placebo had a thromboembolic event including sudden/unwitnessed deaths: 328 (13.1%) vs 390 (15.5%) (hazard ratio, 0.83; 95% CI, 0.72-0.96; P = .01). When sudden/unwitnessed deaths were excluded, the results analyzing thromboembolic events were similar: 153 (6.1%) vs 190 patients (7.6%) with an event (hazard ratio, 0.80; 95% CI, 0.64-0.98; P = .04). CONCLUSIONS AND RELEVANCE: In this study, thromboembolic events occurred frequently in patients with HF, CAD, and sinus rhythm. Rivaroxaban may reduce the risk of thromboembolic events in this population, but these events are not the major cause of morbidity and mortality in patients with recent worsening of HF for which rivaroxaban had no effect. While consistent with other studies, these results require confirmation in prospective randomized clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01877915.
引用
- Greenberg B, Neaton JD, Anker SD, et al. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol. 2019. PMID: 31017637. doi:10.1001/jamacardio.2019.1049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。